Amphastar Pharmaceuticals (AMPH) Return on Capital Employed (2014 - 2026)
Amphastar Pharmaceuticals (AMPH) posted quarterly Return on Capital Employed of 7.92% for Q1 2026, down 596.0% year-over-year from 1.6% in Q1 2025, and down 15.99% quarter-over-quarter from 9.43% in Q4 2025.
Amphastar Pharmaceuticals (AMPH) Return on Capital Employed (2014 - 2026) Analysis & Trends
Amphastar Pharmaceuticals' Return on Capital Employed history runs 13 years deep, the most recent figure standing at 7.92% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 596.0% year-over-year to 7.92%; the TTM figure through Mar 2026 stood at 7.92% (down 596.0% YoY), while the FY2025 annual figure was 9.71%, down 526.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 7.92%, down from 9.43% in the prior quarter.
- The five-year high for Return on Capital Employed was 18.29% in Q1 2023, with the low at 7.92% in Q1 2026.
- The 5-year median for Return on Capital Employed is 15.07% (2022), against an average of 14.32%.
- The sharpest annual moves came in 2022 and 2026: Return on Capital Employed soared 1132 bps in 2022, then plunged 596 bps in 2026.
- Amphastar Pharmaceuticals' Return on Capital Employed stood at 16.81% in 2022, then declined by 10 bps to 15.11% in 2023, then retreated by 2 bps to 14.8% in 2024, then slumped by 36 bps to 9.43% in 2025, then slipped by 16 bps to 7.92% in 2026.
- Business Quant data shows AMPH's Return on Capital Employed at 7.92% in Q1 2026, 9.43% in Q4 2025, and 10.44% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 6.60% |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 17.16% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 6.07% |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 22.04% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -0.29% |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 18.67% |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 5.52% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | Amphastar Pharmaceuticals | 937.87 Mn | 647.74 Mn | 93.47 Mn | 7.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.98% |
| Mar 31, 2026 | 7.92% |
| Dec 31, 2025 | 9.43% |
| Sep 30, 2025 | 10.44% |
| Jun 30, 2025 | 12.58% |
| Mar 31, 2025 | 13.88% |
| Dec 31, 2024 | 14.80% |
| Sep 30, 2024 | 15.76% |
| Jun 30, 2024 | 16.47% |
| Mar 31, 2024 | 16.42% |
| Dec 31, 2023 | 15.11% |
| Sep 30, 2023 | 15.03% |
| Jun 30, 2023 | 15.93% |
| Mar 31, 2023 | 18.29% |
| Dec 31, 2022 | 16.81% |
| Sep 30, 2022 | 15.07% |
| Jun 30, 2022 | 15.49% |
| Mar 31, 2022 | 14.01% |
| Dec 31, 2021 | 12.53% |
| Sep 30, 2021 | 8.65% |